GlaxoSmithKline Pharmaceuticals Ltd reports Q2 FY27 revenue of ₹1,180 crore, up 21%, and PAT of ₹335 crore, up 31% year on year
- EBITDA grew 20% year on year.
- Growth was reported across General Medicines, Vaccines and Specialty Medicines.
- The company plans to launch BLENREP in India.